-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Wedbush Lowers AnaptysBio's PT to $29 From $32, Removes Valuations for Rosnilimab in Rheumatoid Arthritis, ANB032 in Atopic Dermatitis; Keeps Neutral Rating

Wedbush Lowers AnaptysBio's PT to $29 From $32, Removes Valuations for Rosnilimab in Rheumatoid Arthritis, ANB032 in Atopic Dermatitis; Keeps Neutral Rating

MT Newswires · 01/06/2023 03:00